A randomised multicentre phase II trial comparing adjuvant therapy in patients with resected pancreatic adenocarcinoma treated with interferon alpha-2b and 5-fluorouracil (5-FU) [fluorouracil] alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival

Trial Profile

A randomised multicentre phase II trial comparing adjuvant therapy in patients with resected pancreatic adenocarcinoma treated with interferon alpha-2b and 5-fluorouracil (5-FU) [fluorouracil] alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2013

At a glance

  • Drugs Fluorouracil (Primary) ; Interferon alpha-2b (Primary) ; Cisplatin
  • Indications Pancreatic cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms CapRI-II
  • Most Recent Events

    • 05 Apr 2011 Status changed from recruiting to discontinued, according to ISRCTN Current Controlled Trials.
    • 11 Mar 2009 Planned end date changed from 1 Mar 2012 to 1 Apr 2012 as reported by ISRCTN: Current Controlled Trials.
    • 11 Mar 2009 Actual initiation date (Oct 2008) added as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top